Iovance shares jump on buyout rumors

Immuno-oncology biotech Iovance Biotherapeutics’ shares rocketed up by nearly 40% Tuesday on buyout chatter.

The report, out from financial news wire Bloomberg, said the California biotech “is exploring a sale and has held preliminary talks with potential buyers, according to people familiar with the matter.”